Pharma in Brief

DECEMBER 3, 2023

This year marks the 30-year anniversary of the Patented Medicines (Notice of Compliance) Regulations ( Regulations ), introduced in 1993 to prevent patent infringement by linking the regulatory approval of generic or biosimilar drugs with the patent rights of innovators.

Regulation 52

Regulation Compliance Medicine Manufacturing 52

The Pharma Data

MAY 8, 2021

The Sandoz division has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

MARCH 15, 2022

“Today’s approval of the first generic for one of the most commonly prescribed complex drug-device combination products to treat asthma and COPD is another step forward in our commitment to bring generic copies of complex drugs to the market, which can improve quality of life and help reduce the cost of treatment,” said Sally Choe, Ph.D.,

FDA Approval 52

FDA Approval Generic Drugs Production Drugs 52

The Pharma Data

MAY 2, 2021

With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. The Sandoz division has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. Disclaimer.

Clinical Development 40

Clinical Development Medicine Development Production 40

The Pharma Data

MAY 18, 2021

By modernizing and simplifying its manufacturing setup, Sandoz will improve its ability to consistently deliver high-quality medicines to patients, while remaining cost-competitive on the global market. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. About Sandoz.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

The Pharma Data

MAY 15, 2023

Before joining EMMI Group as CEO, he was a Member of the Executive Board and Head of the Marketing Department at Migros-Genossenschafts-Bund. He holds a Master degree in Marketing and Trade from the University of St. Urs Riedener, was CEO of Swiss consumer goods company EMMI Group between 2008 and 2022. Gallen (HSG), Switzerland.

Sales 40

Sales Production Doctors Doctor 40

XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. is a global pharmaceutical company, working across both developed and emerging markets. It contains the antiviral medications nirmatrelvir and ritonavir.

Sales 98

Sales Manufacturing FDA Approval Life Science 98